Literature DB >> 11283405

Resolution of stroke deficits following contralateral grafts of conditionally immortal neuroepithelial stem cells.

T Veizovic1, J S Beech, R P Stroemer, W P Watson, H Hodges.   

Abstract

BACKGROUND AND
PURPOSE: Grafts of MHP36 cells have previously been shown to reduce dysfunction after global ischemia in rats. To test their efficacy after focal ischemia, MHP36 cells were grafted 2 to 3 weeks after transient intraluminal middle cerebral artery occlusion (tMCAO) in rats.
METHODS: MHP36 cells were implanted into the hemisphere contralateral to the lesion, with 8 deposits of 3 microL of cell suspension (25 000 cells per microliter). Sham grafted rats received equivalent volumes of vehicle. Three groups, sham-operated controls (n=11), MCAO+sham grafts (n=10), and MCAO+MHP36 grafts (n=11), were compared in 3 behavioral tests.
RESULTS: In the bilateral asymmetry test, MCAO+MHP36 grafted rats exhibited neglect before grafting but subsequently showed no significant dysfunction, whereas MCAO+sham grafted rats showed stable sensorimotor deficits over 18 weeks relative to controls. MCAO+sham grafted rats demonstrated spontaneous motor asymmetry and increased rotational bias after injection of dopamine agonists. MCAO+MHP36 and control groups exhibited no bias in either spontaneous or drug-induced rotation. In contrast to motor recovery, MCAO+MHP36 grafted rats showed no improvement relative to MCAO+sham grafted rats in spatial learning and memory in the water maze. MCAO produced large striatal and cortical cavitations in both occluded groups. Lesion volume was significantly reduced (P<0.05) in the MCAO+MHP36 grafted group. The majority of MHP36 cells were identified within the intact grafted hemisphere. However, MHP36 cells were also seen in the cortex, striatum, and corpus callosum of the lesioned hemisphere.
CONCLUSIONS: MHP36 cells may improve functional outcome after MCAO by assisting spontaneous reorganization in both the damaged and intact hemispheres.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11283405     DOI: 10.1161/01.str.32.4.1012

Source DB:  PubMed          Journal:  Stroke        ISSN: 0039-2499            Impact factor:   7.914


  36 in total

1.  Dopaminergic differentiation of the Nurr1-expressing immortalized mesencephalic cell line CSM14.1 in vitro.

Authors:  Stefan Jean-Pierre Haas; Andreas Wree
Journal:  J Anat       Date:  2002-07       Impact factor: 2.610

Review 2.  Migration and fate of therapeutic stem cells in different brain disease models.

Authors:  B J Carney; K Shah
Journal:  Neuroscience       Date:  2011-09-14       Impact factor: 3.590

Review 3.  Cell therapy for stroke.

Authors:  Sean I Savitz; Jonathan H Dinsmore; Lawrence R Wechsler; Daniel M Rosenbaum; Louis R Caplan
Journal:  NeuroRx       Date:  2004-10

4.  A chronic 1 year assessment of MRI contrast agent-labelled neural stem cell transplants in stroke.

Authors:  M Modo; J S Beech; T J Meade; S C R Williams; J Price
Journal:  Neuroimage       Date:  2008-06-25       Impact factor: 6.556

5.  Validity of bone marrow stromal cell expansion by animal serum-free medium for cell transplantation therapy of cerebral infarct in rats-a serial MRI study.

Authors:  Masaki Ito; Satoshi Kuroda; Taku Sugiyama; Hideo Shichinohe; Yukari Takeda; Mitsufumi Nishio; Takao Koike; Kiyohiro Houkin
Journal:  Transl Stroke Res       Date:  2011-07-26       Impact factor: 6.829

6.  MRI stem cell tracking for therapy in experimental cerebral ischemia.

Authors:  Pedro Ramos-Cabrer; Mathias Hoehn
Journal:  Transl Stroke Res       Date:  2011-10-27       Impact factor: 6.829

Review 7.  Stem cell sources for regenerative medicine: the immunological point of view.

Authors:  Olivier Preynat-Seauve; Karl-Heinz Krause
Journal:  Semin Immunopathol       Date:  2011-05-21       Impact factor: 9.623

Review 8.  Cell based therapies for ischemic stroke: from basic science to bedside.

Authors:  Xinfeng Liu; Ruidong Ye; Tao Yan; Shan Ping Yu; Ling Wei; Gelin Xu; Xinying Fan; Yongjun Jiang; R Anne Stetler; George Liu; Jieli Chen
Journal:  Prog Neurobiol       Date:  2013-12-12       Impact factor: 11.685

9.  Potential of adult neural stem cells for cellular therapy.

Authors:  Philippe Taupin
Journal:  Biologics       Date:  2007-03

10.  c-MycERTAM transgene silencing in a genetically modified human neural stem cell line implanted into MCAo rodent brain.

Authors:  Lara Stevanato; Randolph L Corteling; Paul Stroemer; Andrew Hope; Julie Heward; Erik A Miljan; John D Sinden
Journal:  BMC Neurosci       Date:  2009-07-21       Impact factor: 3.288

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.